Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With an Open-label Cohort to Assess the Safety, Tolerability, and Efficacy of Namilumab in Subjects With Active Cardiac Sarcoidosis

NCT05351554 is registered in ClinicalTrials.gov with Kinevant Sciences GmbH as lead sponsor.

NCT NCT05351554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05351554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With an Open-label Cohort to Assess the Safety, Tolerability, and Efficacy of Namilumab in Subjects With Active Cardiac Sarcoidosis
Lead sponsor
Kinevant Sciences GmbH
Phase
Phase 2
Overall status
Terminated
Start date
August 23, 2022
Completion date
December 13, 2022
Enrollment
1 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoidosis, cardiac